Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The prognosis of pancreatic cancer is extremely poor. Current guidelines recommend FOLFIRINOX
or modified-FOLFIRINOX as the first-line chemotherapeutic regimen. Studies have shown that
immunotherapy with Anti-PD-1 antibody can effectively increase the response rate and prolong
patient survival in a number of cancer diseases. Here investigators intend to compare the
therapeutic effects of modified-FOLFIRINOX alone and the combination of modified-FOLFIRINOX
and Anti-PD-1 antibody in patients with borderline resectable and locally advanced pancreatic
cancer.